Eidos Therapeutics, which is developing a novel oral therapy for rare neurodegenerative diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The San Francisco, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol EIDX. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
